生血宝合剂防治老年食管癌患者放疗联合替吉奥化疗后骨髓抑制的疗效  

Efficacy of Shengxuebao mixture in preventing myelosuppression in elderly esophageal cancer patients after radiotherapy combined with tiglio chemotherapy

作　　者：徐潇 朱时敏 潘蒙 平道志 谢添 沈志亮 唐健 钱永红 XU Xiao;ZHU Shimin;PAN Meng;PING Daozhi;XIE Tian;SHEN Zhiliang;TANG Jian;QIAN Yonghong(Radiotherapy Department,Taizhou Hospital of Traditional Chinese Medicine,Jiangsu Province,Taizhou 225300,China)

机构地区：[1]江苏省泰州市中医院放疗科,225300

出　　处：《临床合理用药》2025年第3期17-20,共4页Chinese Journal of Clinical Rational Drug Use

基　　金：江苏省中医药科技发展计划项目(MS2021086);泰州市科技项目(TS202222)。

摘　　要：目的 观察生血宝合剂防治老年食管癌患者放疗联合替吉奥化疗后骨髓抑制的疗效。方法 回顾性选取2021年1月—2023年1月泰州市中医院收治的老年食管癌患者60例,根据治疗方案分为观察组(30例)和对照组(30例)。对照组患者给予放疗同步口服替吉奥化疗,观察组在对照组基础上给予生血宝合剂口服直至放疗结束后1周。比较2组患者的骨髓抑制发生情况,放疗前1 d、放疗第21天、放疗后1 d的血红蛋白(Hb)水平与白细胞计数(WBC)、中性粒细胞计数(NEUT)及血小板计数(PLT),治疗期间不良反应发生情况。结果 观察组骨髓抑制总发生率为40.00%,低于对照组的73.33%(χ^(2)=6.787,P=0.009)。放疗第21天、放疗后1 d, 2组Hb水平与WBC、NEUT、PLT均较放疗前1 d逐渐下降(P<0.05或P<0.01),2组放疗第21天的Hb水平比较差异无统计学意义(P>0.05),但观察组放疗后1 d Hb水平与放疗第21天和放疗后1 d WBC、NEUT、PLT高于对照组(P<0.05或P<0.01)。观察组不良反应总发生率为23.33%,低于对照组的53.33%(χ^(2)=5.711,P=0.017)。结论 生血宝合剂可有效降低老年食管癌放疗联合替吉奥化疗后骨髓抑制发生率,减轻对Hb水平及WBC、NEUT、PLT的影响,且安全性较高。Objective To observe the efficacy of Shengxuebao mixture in preventing myelosuppression in elderly esophageal cancer patients after radiotherapy combined with tiglio chemotherapy.Methods Sixty cases of elderly esophageal cancer patients admitted to Taizhou Hospital of Traditional Chinese Medicine from January 2021 to January 2023 were retrospectively selected,and they were divided into the observation group(30 cases)and the control group(30 cases)according to the treatment plan.The control group was given radiotherapy synchronized with oral tegio chemotherapy,and the observation group was given Shengxuebao mixture oral until 1 week after the end of radiotherapy on the basis of the control group.The occurrence of myelosuppression,Hb level,WBC,NEUT,and PLT in 1 d before radiotherapy,the 21st day of radiotherapy,and 1 d after radiotherapy,and occurrence of adverse reactions during treatment were compared between the two groups.Results The overall incidence of myelosuppression in the observation group was 40.00%,which was lower than the 73.33%in the control group(χ^(2)=6.787,P=0.009).On the 21st day of radiotherapy and 1 d after radiotherapy,the Hb level and WBC,NEUT,PLT of the two groups gradually decreased compared with those 1 d before radiotherapy(P<0.05 or P<0.01),and the comparison of Hb level on the 21st day of radiotherapy between the two groups was not statistically significant(P>0.05),but the Hb level on the 1st day after radiotherapy,as well as the WBC,NEUT and PLT on the 21st day of radiotherapy and the 1st day after radiotherapy in the observation group were higher than those in the control group(P<0.05 or P<0.01).The total incidence of adverse reactions in the observation group was 23.33%,which was lower than 53.33%in the control group(χ^(2)=5.711,P=0.017).Conclusion Shengxuebao mixture can effectively reduce the incidence of myelosuppression after radiotherapy combined with tiglio chemotherapy for elderly esophageal cancer patients,attenuate the effect on Hb level and WBC,NEUT,PLT,and which is safer.

关 键 词：食管癌 老年人 生血宝合剂 放疗 化疗 替吉奥 骨髓抑制 

分 类 号：R73[医药卫生—肿瘤]